期刊文献+

189例替格瑞洛药物不良反应的特点分析 被引量:3

Analysis of the characteristics of adverse drug reactions of ticagrelor in 189 cases
原文传递
导出
摘要 目的分析替格瑞洛药物不良反应(ADRs)发生的特征及可能的影响因素。方法检索中国知网、万方、维普等数据库中关于替格瑞洛ADRs的文献进行统计分析,检索时间截至2019年12月。用回顾性研究方法对患者年龄、性别、用药情况以及ADRs的发生时间、临床表现、处理与转归等指标进行统计分析。结果共纳入159例病例,189例次ADRs;以男性为主(117例,75%);年龄≥51岁有122例(76.73%);累及的器官或系统主要有呼吸系统(91例,48.14%)、皮肤及皮下组织(41例,21.69%)和消化系统(38例,20.11%)等。结论在应用替格瑞洛的过程中应注意加强监测,以减少ADRs的发生。 Objective To analyze the characteristics and possible influencing factors of the occurrence of adverse drug reactions(ADRs)induced by ticagrelor in order to provide references for safe and rational medication.Methods CNKI,Wanfang and VIP databases were searched for ADRs induced by ticagrelor to December 2019.Retrospective study was used to analyze the patient’s age,gender,medication status,occurrence time,clinical manifestation,treatment and outcome of ADRs.Results A total of 159 cases and 189 times of adverse drug reactions were included.There were 117 male patients accounting for 75.0%.Aged patients over 51 years-old showed a higher incidence(n=122,76.73%).The ADRs induced by ticagrelor were the respiratory system(n=91,48.14%),skin and subcutaneous tissue(n=41,21.69%),digestive system(n=38,20.11%).Conclusion In order to reduce the occurrence of ADRs,we should pay attention to strengthen the monitoring during the application of tegrarol.
作者 王鑫 王诗卉 于晓佳 刘丽宏 WANG Xin;WANG Shi-hui;YU Xiao-jia;LIU Li-hong(Department of Pharmacy,Beijing Chaoyang Hospital,Capital Medical University,Beijing 100020,China)
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2020年第19期3134-3136,共3页 The Chinese Journal of Clinical Pharmacology
关键词 替格瑞洛 药物不良反应 文献分析 ticagrelor adverse drug reaction literature analysis
  • 相关文献

参考文献4

二级参考文献88

  • 1王小艳.急性冠脉综合征后6个月死亡和心肌梗死的预测:前瞻性的多国观察性研究(GRACE)[J].中国处方药,2006(11):25-26. 被引量:139
  • 2王小艳.早期强化他汀治疗对急性冠脉综合征的效果[J].中国处方药,2006(11):26-26. 被引量:8
  • 3Collaborative Research Group of Reperfusion Therapy in Acute Myocardial Infarction.重组葡激酶与重组组织型纤溶酶原激活剂治疗急性心肌梗死的随机多中心临床试验[J].中华心血管病杂志,2007,35(8):691-696. 被引量:43
  • 4Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery ( EACTS ), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, et al. Guidelines on myocardial revascularization. Eur Heart J,2010 , 31:2501-2555.
  • 5Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/ SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation, 2011, 124 :e574-651.
  • 6Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coil Cardiol, 2011,58 :e123-210.
  • 7Nashef SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation ( EuroSCORE ). Eur J Cardiothorac Surg, 1999,16:9-13.
  • 8Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med, 2009,360:961- 972.
  • 9Peterson ED, Dai D, DeLong ER, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coil Cardiol,2010,55:1923-1932.
  • 10Online STS fish calculator [ S/OL]. [ 2012-01-01 ]. http:// riskcalc, sts. org/STSWebRiskCalc273/de, aspx.

共引文献3300

同被引文献51

引证文献3

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部